{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:48Z","timestamp":1786681848396,"version":"build-2736575974"},"reference-count":101,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23CDA1046240"],"award-info":[{"award-number":["23CDA1046240"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"award":["23CDA1046240"],"award-info":[{"award-number":["23CDA1046240"]}],"id":[{"id":"https:\/\/ror.org\/013kjyp64","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["K12TR004411"],"award-info":[{"award-number":["K12TR004411"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"award":["K12TR004411"],"award-info":[{"award-number":["K12TR004411"]}],"id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Dev. Dis.","JCDD"],"abstract":"<jats:p>Over the last decade, immunotherapy has transformed oncology, with an ever-expanding list of indications. As with any therapeutic class, these agents are accompanied by adverse events that are increasingly recognized and pose new challenges for patient care expanding the scope of cardio-oncology. Using the PubMed database, this narrative review summarizes the cardiovascular adverse events associated with the most commonly used immunotherapies, immune checkpoint inhibitors (ICIs), with a focus on the mechanisms, epidemiology, diagnosis, treatment, and monitoring of ICI-associated myocarditis. We also review accelerated atherosclerotic disease, heart failure, cardiomyopathy (including stress-induced cardiomyopathy), arrhythmias, and pericardial disease related to ICI therapy. Finally, we outline CAR T-cell therapy associated cardiotoxicity, including cytokine release syndrome.<\/jats:p>","DOI":"10.3390\/jcdd13080385","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:45:06Z","timestamp":1786545906000},"page":"385","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.3390","volume":"13","author":[{"given":"Ahmad","family":"Naser","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Ashraf","family":"Morgan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY 10467, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs: From CTLA-4 to PD-1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","article-title":"Recent advances and discoveries in the mechanisms and functions of CAR T cells","volume":"21","author":"Larson","year":"2021","journal-title":"Nat. Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lv, Y., Luo, X., Xie, Z., Qiu, J., Yang, J., Deng, Y., Long, R., Tang, G., Zhang, C., and Zuo, J. (2024). Prospects and challenges of CAR-T cell therapy combined with ICIs. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1368732"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1053\/j.seminoncol.2010.09.015","article-title":"Development of ipilimumab: Contribution to a new paradigm for cancer immunotherapy","volume":"37","author":"Hoos","year":"2010","journal-title":"Semin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"k4226","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: Systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamaoncol.2024.3065","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: A systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s11886-023-01854-1","article-title":"Immune cells in cardiac injury repair and remodeling","volume":"25","author":"Zambrano","year":"2023","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.jacbts.2022.05.006","article-title":"The programmed death-1 signaling axis modulates inflammation and LV structure\/function in a stress-induced cardiomyopathy model","volume":"7","author":"Hayashi","year":"2022","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: Elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1161\/CIRCRESAHA.120.315894","article-title":"Mechanisms of cardiovascular toxicities associated with immunotherapies","volume":"128","author":"Baik","year":"2021","journal-title":"Circ. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1158\/1078-0432.CCR-18-2795","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Baban, B., Liu, J.Y., Qin, X., Weintraub, N.L., and Mozaffari, M.S. (2015). Upregulation of programmed death-1 and its ligand in cardiac injury models: Interaction with GADD153. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124059"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Liu, S., Gao, W., Ning, Y., Zou, X., Zhang, W., Zeng, L., and Liu, J. (2022). Cardiovascular toxicity with PD-1\/PD-L1 inhibitors in cancer patients: A systematic review and meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.908173"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Liu, M., Cheng, X., Ni, R., Zheng, B., Huang, S., and Yang, J. (2022). Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1006860"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/ejhf.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis","volume":"23","author":"Castillo","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2021.01.043","article-title":"Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomized clinical trials","volume":"148","author":"Agostinetto","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.21037\/tlcr.2017.12.10","article-title":"Evaluation of rare but severe immune-related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A meta-analysis","volume":"6","author":"Hu","year":"2017","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the EHA, ESTRO, and IC-OS","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/ehf2.15131","article-title":"Long-term cardiovascular outcomes of immune checkpoint inhibitor\u2013related myocarditis: A large single-centre analysis","volume":"12","author":"Braghieri","year":"2024","journal-title":"ESC. Heart Fail."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Cao, W., Han, S., Zhang, P., Mi, L., Wang, Y., Nie, J., Dai, L., Hu, W., Zhang, J., and Chen, X. (2025). Immune checkpoint inhibitor\u2013related myocarditis in patients with lung cancer. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13997-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor\u2013related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e70154","DOI":"10.1002\/clc.70154","article-title":"Immune checkpoint inhibitor-related myocarditis: A single-center observational registry","volume":"48","author":"Alexander","year":"2025","journal-title":"Clin. Cardiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: Proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1093\/eurheartj\/eht210","article-title":"Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"34","author":"Caforio","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","article-title":"Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor\u2013related myocarditis","volume":"75","author":"Awadalla","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1016\/j.jcmg.2022.06.014","article-title":"Global circumferential and radial strain among patients with immune checkpoint inhibitor myocarditis","volume":"15","author":"Quinaglia","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/ehjci\/jeaa345","article-title":"Role of cardiovascular magnetic resonance imaging in cardio-oncology","volume":"22","author":"Saunderson","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","article-title":"Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity","volume":"136","author":"Escudier","year":"2017","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","article-title":"Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Zhang","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor\u2013associated myocarditis","volume":"141","author":"Zhang","year":"2020","journal-title":"Circulation"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","article-title":"Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor\u2013associated myocarditis","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0046-8177(87)80363-5","article-title":"Myocarditis: The Dallas criteria","volume":"18","year":"1987","journal-title":"Hum. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","article-title":"Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor\u2013induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN Guidelines Insights: Management of immunotherapy-related toxicities","volume":"18","author":"Thompson","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/eurheartj\/ehaf192","article-title":"2025 ESC Guidelines for the management of myocarditis and pericarditis: Developed by the task force for the management of myocarditis and pericarditis of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"46","author":"Collini","year":"2025","journal-title":"Eur. Heart J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1001\/jamaoncol.2025.4543","article-title":"Immune Checkpoint Inhibitor\u2013Associated Cardiovascular Toxic Effects: International Cardio-Oncology Society Position Statement","volume":"12","author":"Herrmann","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"114027","DOI":"10.1016\/j.ejca.2024.114027","article-title":"Novel use of abatacept and ruxolitinib as salvage therapy in steroid-refractory immune-related myocarditis, myasthenia, and myositis syndrome","volume":"202","author":"Byer","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_55","unstructured":"clinicaltrials.gov (2025, September 04). Assistance Publique\u2014H\u00f4pitaux de Paris. AbataCept for the Treatment of Immune-Checkpoint Inhibitors Induced mYocarditiS [Internet]. Report No.: NCT05195645, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05195645."},{"key":"ref_56","unstructured":"clinicaltrials.gov, and Neilan, T.G. (2025, September 04). AbatacepT for ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis [Internet]. Report No.: NCT05335928, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05335928."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jaccao.2021.01.004","article-title":"Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors","volume":"3","author":"Waliany","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_58","first-page":"10","article-title":"Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: A retrospective analysis of patients at an academic tertiary care center","volume":"7","author":"Waheed","year":"2021","journal-title":"Cardio-Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12916-024-03261-x","article-title":"Immune checkpoint inhibitors in cancer: The increased risk of atherosclerotic cardiovascular disease events and progression of coronary artery calcium","volume":"22","author":"Gong","year":"2024","journal-title":"BMC Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1038\/s44161-024-00563-4","article-title":"Immune checkpoint landscape of human atherosclerosis and influence of cardiometabolic factors","volume":"3","author":"Das","year":"2024","journal-title":"Nat. Cardiovasc. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","article-title":"Visualizing immune checkpoint inhibitor\u2013derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"107148","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jaccao.2022.11.011","article-title":"Atherosclerosis with immune checkpoint inhibitor therapy: Evidence, diagnosis, and management: JACC CardioOncology State-of-the-Art Review","volume":"4","author":"Zanni","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_65","first-page":"3","article-title":"Cardiotoxicity risk factors with immune checkpoint inhibitors","volume":"8","author":"Brumberger","year":"2022","journal-title":"Cardio-Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"100252","DOI":"10.1016\/j.esmoop.2021.100252","article-title":"Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States","volume":"6","author":"Jain","year":"2021","journal-title":"ESMO Open"},{"key":"ref_67","first-page":"21","article-title":"The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment: Including myocarditis and the new entity of non-inflammatory left ventricular dysfunction","volume":"8","author":"Andres","year":"2022","journal-title":"Cardio-Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u2014A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur. J. Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"A395","DOI":"10.1016\/j.chest.2021.12.425","article-title":"Dilated cardiomyopathy associated with immune checkpoint inhibitor, nivolumab","volume":"161","author":"McCann","year":"2022","journal-title":"Chest"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA-4 and PD-1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0008-6363(03)00437-1","article-title":"Myocarditis and dilated cardiomyopathy: An inflammatory link","volume":"60","author":"Mason","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"111611","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune checkpoint inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"101881","DOI":"10.1016\/j.jaccas.2023.101881","article-title":"Immune checkpoint inhibitor-related stress cardiomyopathy: Differential diagnosis and key role of cardiac imaging","volume":"16","author":"Cobarro","year":"2023","journal-title":"JACC Case Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: Endomyocardial biopsy provides pathological insights to dual diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ejhf.2400","article-title":"Pathophysiology of Takotsubo syndrome: A joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology","volume":"24","author":"Omerovic","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1002\/cam4.5438","article-title":"Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"ehae666.3771","DOI":"10.1093\/eurheartj\/ehae666.3771","article-title":"Interleukin-6 levels in atrium and onset of spontaneous atrial fibrillation: Is there a causal relationship","volume":"45","author":"Wu","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2169\/internalmedicine.5317-20","article-title":"Cytokine expression in patients with cardiac complication after immune checkpoint inhibitor therapy","volume":"60","author":"Tsuruda","year":"2021","journal-title":"Intern. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"100575","DOI":"10.1016\/j.cophys.2022.100575","article-title":"Cardiac fibrosis in oncologic therapies","volume":"29","author":"Packard","year":"2022","journal-title":"Curr. Opin. Physiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ma, Z., Pei, J., Sun, X., Liu, L., Lu, W., Guo, Q., Lyu, J., Liu, Y., Zhang, Y., and Zhao, Z. (2021). Pericardial toxicities associated with immune checkpoint inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.663088"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"ytab002","DOI":"10.1093\/ehjcr\/ytab002","article-title":"Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: A case report","volume":"5","author":"Moriyama","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_84","first-page":"29","article-title":"Immune checkpoint inhibitors and pericardial disease: A systematic review","volume":"10","author":"Mudra","year":"2024","journal-title":"Cardio-Oncol."},{"key":"ref_85","first-page":"26","article-title":"Incidence and survival outcomes of myocarditis and pericardial diseases associated with immune checkpoint inhibitor therapy","volume":"11","author":"Ozaki","year":"2025","journal-title":"Cardio-Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s10120-025-01582-1","article-title":"Cardiovascular and thromboembolic outcomes with immune checkpoint inhibitors in gastroesophageal cancer: A propensity score\u2013matched cohort study","volume":"28","author":"Bahar","year":"2025","journal-title":"Gastric Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_89","first-page":"18","article-title":"Inflammation and acute cardiotoxicity in adult hematological patients treated with CAR-T cells: Results from a pilot proof-of-concept study","volume":"10","author":"Camilli","year":"2024","journal-title":"Cardio-Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/ejh.14088","article-title":"Myocardial strain is associated with adverse cardiac events in patients treated with chimeric antigen receptor (CAR) T-cell therapy","volume":"112","author":"Patel","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/ejh.14289","article-title":"The cardiotoxic effects of CAR-T cell therapy: An updated systematic review and meta-analysis","volume":"113","author":"Mazetto","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_93","first-page":"616","article-title":"Cardiotoxicity of T-cell antineoplastic therapies: JACC: CardioOncology primer","volume":"4","author":"Ganatra","year":"2022","journal-title":"Cardio-Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cyto.2014.12.024","article-title":"The varying faces of IL-6: From cardiac protection to cardiac failure","volume":"74","author":"Fontes","year":"2015","journal-title":"Cytokine"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41569-026-01265-z","article-title":"Cardiotoxicity of T cell immunotherapies","volume":"23","author":"Raddatz","year":"2026","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"24821","DOI":"10.1038\/s41598-024-76829-5","article-title":"A multimodality score strategy for assessing the risk of immune checkpoint inhibitors related cardiotoxicity","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1007\/s12012-025-09990-6","article-title":"Predicting 30-day cardiotoxicity in patients receiving immune checkpoint inhibitors: An observational study utilizing XGBoost","volume":"25","author":"Li","year":"2025","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"118","DOI":"10.21037\/tlcr-2025-aw-1252","article-title":"Development and external validation of a multivariable nomogram for predicting severe immune checkpoint inhibitor-associated myocarditis in advanced lung cancer","volume":"15","author":"Luan","year":"2026","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/eurheartj\/ehaf315","article-title":"Immune checkpoint inhibitor-associated myocarditis: A novel risk score","volume":"47","author":"Power","year":"2026","journal-title":"Eur. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ejh.70040","article-title":"Predictive Factors and Baseline Risk Stratification for CAR-T Cell Therapy-Related Cardiovascular Toxicity","volume":"116","author":"Farmakis","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ye, L., Liao, L., Wang, L., Zhao, X., Zeng, J., and Xu, X. (2026). Prediction models for CAR-T Cell therapy-related adverse events in hematologic malignancies: A systematic review and meta-analysis. BMC Cancer, 26.","DOI":"10.1186\/s12885-026-15877-8"}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/385\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:21:42Z","timestamp":1786681302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/13\/8\/385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":101,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcdd13080385"],"URL":"https:\/\/doi.org\/10.3390\/jcdd13080385","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}